171 related articles for article (PubMed ID: 28315807)
21. Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data.
Smith RL; Haslemo T; Refsum H; Molden E
Eur J Clin Pharmacol; 2016 Sep; 72(9):1099-104. PubMed ID: 27353638
[TBL] [Abstract][Full Text] [Related]
22. Relevance of CYP2C9 Function in Valproate Therapy.
Monostory K; Nagy A; Tóth K; Bűdi T; Kiss Á; Déri M; Csukly G
Curr Neuropharmacol; 2019; 17(1):99-106. PubMed ID: 29119932
[TBL] [Abstract][Full Text] [Related]
23. Impact of Age and Genotype on Serum Concentrations of Valproic Acid and Its Hepatotoxic Metabolites in Chinese Pediatric Patients With Epilepsy.
Zhao M; Chen Y; Wang M; Li G; Zhao L
Ther Drug Monit; 2020 Oct; 42(5):760-765. PubMed ID: 32107351
[TBL] [Abstract][Full Text] [Related]
24. Association of Valproic Acid and Its Main Metabolites' Plasma Concentrations with Clinical Outcomes among Epilepsy Patients: A 10-Year Retrospective Study Based on Therapeutic Drug Monitoring.
Li RT; Chen ZY; Tang SY; Wen DS; Ren RN; Zhang XX; Liu SZ; Zhou S; Wang XD; Zhou LM; Huang M
Drug Metab Dispos; 2024 Feb; 52(3):210-217. PubMed ID: 38195521
[TBL] [Abstract][Full Text] [Related]
25. Effect of SCN1Aand SCN2A gene polymorphisms on the efficacy of valproic acid treatment in Chinese children with epilepsy.
Bao Z; Li H; Hu J; Zhao R; Yan L; Zheng A
PLoS One; 2024; 19(6):e0304869. PubMed ID: 38837984
[TBL] [Abstract][Full Text] [Related]
26. Effect of UGT2B7 genetic variants on serum valproic acid concentration.
Ma H; Zhang T; Gong Z; Zhou B; Zou M; Xiao S; Zhu W
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Aug; 38(8):766-72. PubMed ID: 23981985
[TBL] [Abstract][Full Text] [Related]
27. Add-on stiripentol elevates serum valproate levels in patients with or without concomitant topiramate therapy.
Jogamoto T; Yamamoto Y; Fukuda M; Suzuki Y; Imai K; Takahashi Y; Inoue Y; Ohtsuka Y
Epilepsy Res; 2017 Feb; 130():7-12. PubMed ID: 28081475
[TBL] [Abstract][Full Text] [Related]
28. Correlation of MCT1 and ABCC2 gene polymorphisms with valproic acid resistance in patients with epilepsy on valproic acid monotherapy.
Chen J; Su Q; Qin J; Zhou Y; Ruan H; Chen Z; Chen Z; Li H; Zhou Y; Zhou S; Wang X; Zhou L; Huang M
Drug Metab Pharmacokinet; 2019 Jun; 34(3):165-171. PubMed ID: 30952578
[TBL] [Abstract][Full Text] [Related]
29. Correlation of GSTP1 rs1695 and CAT rs769217 with elevated AST induced by valproate sodium in Chinese children with epilepsy.
Wang L; Li H; Zeng G; Shi L; Zhu M; Luo J; Zhang Z
Pak J Pharm Sci; 2021 Sep; 34(5):1759-1766. PubMed ID: 34803013
[TBL] [Abstract][Full Text] [Related]
30. SCN1A Polymorphisms and Haplotypes Are Associated With Valproic Acid Treatment Outcomes in Chinese Children With Epilepsy.
Zhu J; Lu J; Shen X; He Y; Xia H; Li W; Guo H; Zhang J; Fan X
Pediatr Neurol; 2023 Sep; 146():55-64. PubMed ID: 37451178
[TBL] [Abstract][Full Text] [Related]
31. Influence of acylpeptide hydrolase polymorphisms on valproic acid level in Chinese epilepsy patients.
Wen ZP; Fan SS; Du C; Yin T; Zhou BT; Peng ZF; Xie YY; Zhang W; Chen Y; Tang J; Xiao J; Chen XP
Pharmacogenomics; 2016 Jul; 17(11):1219-1225. PubMed ID: 27406852
[TBL] [Abstract][Full Text] [Related]
32. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.
Inoue K; Takahashi T; Yamamoto Y; Suzuki E; Takahashi Y; Imai K; Inoue Y; Hirai K; Tsuji D; Itoh K
Seizure; 2015 Dec; 33():76-80. PubMed ID: 26599579
[TBL] [Abstract][Full Text] [Related]
33. Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain.
Noai M; Soraoka H; Kajiwara A; Tanamachi Y; Oniki K; Nakagawa K; Ishitsu T; Saruwatari J
Acta Neurol Scand; 2016 Mar; 133(3):216-23. PubMed ID: 26223287
[TBL] [Abstract][Full Text] [Related]
34. Effects of UGT2B7 Genetic Polymorphisms on Serum Concentrations of Valproic Acid in Chinese Children With Epilepsy Comedicated With Lamotrigine.
Wang Q; Zhao L; Liang M; Dong Y; Yun W; Qiu F; Meng H; Guo Y
Ther Drug Monit; 2016 Jun; 38(3):343-9. PubMed ID: 26717295
[TBL] [Abstract][Full Text] [Related]
35. Impact of MDR1 and UGT Gene Polymorphisms on Sodium Valproate Plasma Concentration in Patients with Epilepsy.
Song C; Li X; Zhang H; Bao J; Lu W; Peng Q; Zhang Y
Clin Lab; 2022 Oct; 68(10):. PubMed ID: 36250837
[TBL] [Abstract][Full Text] [Related]
36. CYP2C19 & UGT1A6 genetic polymorphisms and the impact on Valproic acid-induced weight gain in people with epilepsy: Prospective genetic association study.
Mani B; Nair PP; Sekhar A; Kamalanathan S; Narayan SK; Kesavan R
Epilepsy Res; 2021 Nov; 177():106786. PubMed ID: 34656038
[TBL] [Abstract][Full Text] [Related]
37. Polymorphisms of peroxisome proliferator-activated receptor γ (PPARγ) and cluster of differentiation 36 (CD36) associated with valproate-induced obesity in epileptic patients.
Bai X; Xu C; Wen D; Chen Y; Li H; Wang X; Zhou L; Huang M; Jin J
Psychopharmacology (Berl); 2018 Sep; 235(9):2665-2673. PubMed ID: 29984389
[TBL] [Abstract][Full Text] [Related]
38. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes.
Ho PC; Abbott FS; Zanger UM; Chang TK
Pharmacogenomics J; 2003; 3(6):335-42. PubMed ID: 14597963
[TBL] [Abstract][Full Text] [Related]
39. Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese.
Goto S; Seo T; Murata T; Nakada N; Ueda N; Ishitsu T; Nakagawa K
Ther Drug Monit; 2007 Feb; 29(1):118-21. PubMed ID: 17304159
[TBL] [Abstract][Full Text] [Related]
40. Analysis of the Variables Influencing Valproic Acid Concentration in the Serum and Cerebrospinal Fluid of Chinese Patients After Craniotomy.
Li Z; Gao W; Liu G; Chen W
Ther Drug Monit; 2017 Aug; 39(4):450-456. PubMed ID: 28604475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
